Management of uncommon chemotherapy-induced emergencies

The Lancet Oncology

Volumn 12, Issue 8, 2011, Pages 806-814

  Morgan, Carys ^a   Tillett, Tania ^b   Braybrooke, Jeremy ^b   Ajithkumar, Thankamma ^c  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; METHYLPREDNISOLONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PREDNISOLONE; PROCARBAZINE; RETINOIC ACID; TAXANE DERIVATIVE; UNINDEXED DRUG; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEMOLYTIC ANEMIA; ACUTE LIMB ISCHEMIA; ACUTE MESENTERIC ISCHEMIA; ACUTE PANCREATITIS; ACUTE THROMBOCYTOPENIA; ADULT RESPIRATORY DISTRESS SYNDROME; ARTERY OCCLUSION; ARTIFICIAL VENTILATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDITIS; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CHILL; CHOLESTEROL BLOOD LEVEL; COMPLETE HEART BLOCK; CONFUSION; DRUG FEVER; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; ECG ABNORMALITY; ELECTROLYTE DISTURBANCE; GERM CELL TUMOR; HEART ARRHYTHMIA; HEART BLOCK; HEART BUNDLE BRANCH BLOCK; HEART INFARCTION; HEART PACING; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC PANCARDITIS; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; HYPOMAGNESEMIA; HYPOTENSION; INTERSTITIAL PNEUMONIA; LIMB ISCHEMIA; LIVER VENOOCCLUSIVE DISEASE; LUNG CANCER; LUNG EMBOLISM; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MESENTERIC ARTERY OCCLUSION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIC ENTEROCOLITIS; OCCLUSIVE CEREBROVASCULAR DISEASE; PANCREATITIS; PLEURECTOMY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SOLID TUMOR; SPONTANEOUS PNEUMOTHORAX; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; TESTIS TUMOR; THORACOTOMY; THORAX DRAINAGE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOXIC EPIDERMAL NECROLYSIS; TOXIC MEGACOLON; VASCULAR DISEASE; VASOSPASM; VEIN EMBOLISM; WHEEZING;

ANTINEOPLASTIC AGENTS; DRUG TOXICITY; EMERGENCIES; HUMANS; NEOPLASMS;

EID: 79960892452     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70208-4     Document Type: Review

References (83)

1. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC Cardiac disturbances during the administration of taxol. J Clin Oncol 1991, 9:1704-1712.
2. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993, 20:1-15.
3. Rowinsky EK, Donehower RC Paclitaxel (taxol). N Engl J Med 1995, 332:1004-1014.
4. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM Acute arrhythmogenicity of doxorubicin administration. Cancer 1987, 60:1213-1218.
5. Rudzinski T, Ciesielczyk M, Religa W, Bednarkiewicz Z, Krzeminska-Pakula M Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator. Europace 2007, 9:278-280.
6. Kilickap S, Akgul E, Aksoy S, Aytemir K, Barista I Doxorubicin-induced second degree and complete atrioventricular block. Europace 2005, 7:227-230.
7. Quezado ZM, Wilson WH, Cunnion RE, et al. Highdose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993, 118:31-36.
8. Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 1989, 24:395-396.
9. Aziz SA, Tramboo NA, Mohi-ud-Din K, Iqbal K, Jalal S, Ahmad M Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. Clin Oncol (R Coll Radiol) 1998, 10:377-378.
10. Tayer-Shifman OE, Rottenberg Y, Shuvy M Gemcitabine-induced supraventricular tachycardia. Tumori 2009, 95:547-549.
11. Tassinari D, Sartori S, Drudi G, et al. Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature. Ann Oncol 1997, 8:1263-1267.
12. Tassinari D, Sartori S, Drudi G, et al. Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature. Ann Oncol 1997, 8:1263-1267.
13. Stein ME, Shklar Z, Drumea K, Goralnik L, Ben-Arieh Y, Haim N Chemotherapy induced spontaneous pneumothorax in a patient with bulky mediastinal lymphoma: a rare oncologic emergency. Oncology 1997, 54:15-18.
14. Lote K, Dahl O, Vigander T Pneumothorax during combination chemotherapy. Cancer 1981, 47:1743-1745.
15. Hsu JR, Chang SC, Perng RP Pneumothorax following cytotoxic chemotherapy in malignant lymphoma. Chest 1990, 98:1512-1513.
16. Fenlon HM, Carney D, Breatnach E Case report: bilateral recurrent tension pneumothorax complicating combination chemotherapy for soft tissue sarcoma. Clin Radiol 1996, 51:302-304.
17. Helmkamp BF, Beecham JB, Wandtke JC, Keys H Spontaneous pneumothorax in gynecologic malignancies. Am J Obstet Gynecol 1982, 142:706-707.
18. Sleijfer S Bleomycin-induced pneumonitis. Chest 2001, 120:617-624.
19. Bloor AJ, Seale JR, Marcus RE Two cases of fatal bleomycin pneumonitis complicating the treatment of non-Hodgkin's lymphoma. Clin Lab Haematol 1998, 20:119-121.
20. Onuma T, Holland JF, Masuda H, Waligunda JA, Goldberg GA Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer 1974, 33:1230-1238.
21. Bleomycin (accessed Jan 10, 2011). http://www.bccancer.bc.ca/NR/rdonlyres/7D172F85-5705-4D07-9941-44A88120E52D/32999/Bleomycin_monograph_1Mar09_formatted1.pdf.
22. Khan A, McNally D, Tutschka PJ, Bilgrami S Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother 1997, 31:1471-1474.
23. Davidoff S, Shah RD, Arunabh T Gemcitabine-induced respiratory failure associated with elevated erythrocyte sedimentation rate (ESR). Respir Med 2006, 100:760-763.
24. Pavlakis N, Bell DR, Millward MJ, Levi JA Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997, 80:286-291.
25. Linskens RKGR, van Groeningen CJ, Giaccone G Severe lung injury induced by gemcitabine. Neth J Med 2000, 56:232-235.
26. Salvucci M, Zanchini R, Molinari A, et al. Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone treatment for acute leukemia. Haematologica 2000, 85:769-770.
27. Kopterides P, Lignos M, Mentzelopoulos S, Armaganidis A, Pappa V Cytarabine induced lung injury: case report. Anticancer Drugs 2005, 16:743-745.
28. Brieva J Cyclophosphamide-induced acute respiratory distress syndrome. Respirology 2007, 12:769-773.
29. Dai MS, Ho CL, Chen YC, Kao WY, Chao TY Acute respiratory distress syndrome following intrathecal methotrexate administration: a case report and review of literature. Ann Hematol 2000, 79:696-699.
30. Prat A, Martínez P, Serrano C, Montero MA, Andreu J, Cortés J Acute Lung Injury. Associated with Docetaxel and Bevacizumab. Clin Oncol 2007, 19:803-805.
31. Nelson RTP Dyspnoea with gemcitabine is commonly seen, often disease related, transient and rarely severe. Eur J Cancer 1995, 31(suppl 6):197-198.
32. Leaver SKET Acute respiratory distress syndrome. BMJ 2007, 335:389-394.
33. Desrame J, Broustet H, de Tailly P Darodes, Girard D, Saissy JM Oxaliplatin induced haemolytic anaemia. Lancet 1999, 354:1179-1180.
34. Sorbye H, Bruserud Y, Dahl O Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncol 2001, 40:882-883.
35. Curtis BR, Kaliszewski J, Marques MB, et al. Immune mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 2006, 81:193-198.
36. Zorrilla AF Cardona, Herault L Reveiz, Casasbuenas A, Aponte DM, Ramos PL Systematic review of case reports concerning adults suffering from neutropenic enterocolitis. Clin Transl Oncol 2006, 8:31-38.
37. Furonaka M, Miyazaki M, Nakajima M, et al. Neutropenic enterocolitis in lung cancer: a report of two cases and a review of the literature. Intern Med 2005, 44:467-470.
38. Gadducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature. Anticancer Res 2005, 25:2509-2513.
39. Kouroussis C, Samonis G, Androulakis N, et al. Successful conservative treatment of neutropenic enterocolitis complicating taxanebased chemotherapy: a report of five cases. Am J Clin Oncol 2000, 23:309-313.
40. Wodzinski MA, Snowden JA, Reilly JT Toxic megacolon complicating chemotherapy for acute myeloid leukaemia. Postgrad Med J 1994, 70:921-923.
41. Cronin CG, O'Connor M, Lohan DG, et al. Imaging of the gastrointestinal complications of systemic chemotherapy. Clin Radiol 2009, 64:724-733.
42. Dietrich CF, Hermann S, Klein S, Braden B Sonographic signs of neutropenic enterocolitis. World J Gastroenterol 2006, 12:1397-1402.
43. Wodzinski MA, Snowden JA, Reilly JT Toxic megacolon complicating chemotherapy for acute myeloid leukaemia. Postgrad Med J 1994, 70:921-923.
44. Velanovich V, LaPorta AJ, Garrett WL, Richards TB, Cornett PA Pseudomembranous colitis leading to toxic megacolon associated with antineoplastic chemotherapy. Report of a case and review of the literature. Dis Colon Rectum 1992, 35:369-372.
45. de Gara CJ, Gagic N, Arnold A, Seaton T Toxic megacolon associated with anticancer chemotherapy. Can J Surg 1991, 34:339-341.
46. Kumar DM, Sundar S, Vasanthan S A case of paclitaxel-induced pancreatitis. Clin Oncol (R Coll Radiol) 2003, 15:35.
47. Mills KM, Johnson DM, Middlebrooks M, Burton GV Possible drug-associated pancreatitis after paclitaxel-cremophor administration. Pharmacotherapy 2000, 20:95-97.
48. McGrail LH, Sehn LH, Weiss RB, Robson MR, Antin JH, Byrd JC Pancreatitis during therapy of acute myeloid leukemia: cytarabine related?. Ann Oncol 1999, 10:1373-1376.
49. Li SH, Chen WH, Tang Y, et al. Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients. Clin Neurol Neurosurg 2006, 108:150-156.
50. Saynak M, Cosar-Alas R, Yurut-Caloglu V, Caloglu M, Kocak Z, Uzal C Chemotherapy and cerebrovascular disease. J BUON 2008, 13:31-36.
51. Bosl GJ, Leitner SP, Atlas SA, Sealey JE, Preibisz JJ, Scheiner E Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol 1986, 4:1684-1689.
52. Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992, 10:1386-1389.
53. Ruiz MA, Marugan I, Estellés A, et al. The influence of chemotherapy on plasma coagulation and fibrinolytic systems in lung cancer patients. Cancer 1989, 63:643-648.
54. Vezmar S, Becker A, Bode U, Jaehde U Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003, 49:92-104.
55. Feinberg WM, Swenson MR Cerebrovascular complications of L-asparaginase therapy. Neurology 1988, 38:127-133.
56. Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Bohles H Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2003, 25:484-487.
57. Earl M Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2009, 7:600-606.
58. Earl M Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2009, 7:600-606.
59. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996, 334:494-500.
60. Renard D, Westhovens R, Vandenbussche E, Vandenberghe R Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 2004, 251:226-228.
61. Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004, 77:72-76.
62. Edwards MJJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM Reversible posterior leucoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol 2001, 12:1327-1329.
63. Susser WS, Whitaker-Worth DL, Grant-Kels JM Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999, 40:367-398.
64. Chia FL, Leong KP Severe cutaneous adverse reactions to drugs. Curr Opin Allergy Clin Immunol 2007, 7:304-309.
65. Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984, 101:41-44.
66. Saif MW, Shahrokni A, Cornfeld D Gemcitabine-induced liver fibrosis in a patient with pancreatic cancer. JOP 2007, 8:460-467.
67. Hengge UR, Brockmeyer NH, Rasshofer R, Goos M Fatal hepatic failure with liposomal doxorubicin. Lancet 1993, 341:383-384.
68. de Jonge ME, Huitema AD, Beijnen JH, Rodenhuis S High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006, 94:1226-1230.
69. Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999, 5:306-315.
70. Dressel D, Ritter CA, Sperker B, et al. Busulfan induces activin A expression in vitro and in vivo: a possible link to venous occlusive disease. Clin Pharmacol Ther 2003, 74:264-274.
71. Boula AM, Mantadakis E, Xilouri IM, Christoforidou AV, Foudoulakis AM, Samonis G Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine. Am J Hematol 2005, 79:216-219.
72. Kagohashi K, Funayama Y, Satoh H, Sekizawa K Fatal hepatic failure due to gemcitabine and vinorelbine. Ann Oncol 2003, 14:960.
73. King PD, Perry MC Hepatotoxicity of chemotherapy. Oncologist 2001, 6:162-176.
74. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004, 30:181-191.
75. Batra R, Davies JN, Wheatley D Extensive arterial and venous thrombo-embolism with chemotherapy for testicular cancer: a case report. Cases J 2009, 2:9082.
76. Samuels BL, Vogelzang NJ, Kennedy BJ Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987, 19:253-256.
77. Cool RM, Herrington JD, Wong L Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide. Pharmacotherapy 2002, 22:1200-1204.
78. Longo F, Mansueto G, Poggi A, et al. Acute arterial thrombosis in a patient with small cell lung cancer after a cycle of chemotherapy with cisplatin and etoposide. Tumori 1999, 85:214-215.
79. Mathews J, Goel R, Evans WK, Shamji F, Stewart DJ Arterial occlusion in patients with peripheral vascular disease treated with platinum-based regimens for lung cancer. Cancer Chemother Pharmacol 1997, 40:19-22.
80. Molloy RG, Welch GC, Drury JK, Abel BJ Arterial thrombosis after chemotherapy with cisplatin, vinblastine and methotrexate. Br J Clin Pract 1995, 49:50-51.
81. Yeung KK, Coster E, Vos AW Floris, Van der Vijgh RK, Linsen MA, Wisselink W Repeated arterial thrombosis as a complication of carboplatin-based chemotherapy. Vascular 2006, 14:51-54.
82. Allerton R Acute mesenteric ischaemia associated with 5-FU, cisplatin and vincristine chemotherapy. Clin Oncol (R Coll Radiol) 1996, 8:116-117.
83. Sugden EM, Griffiths CL, Greywoode GI, Lewis SM Acute abdomen during adjuvant chemotherapy: superior mesenteric artery thrombosis associated with CMF chemotherapy. Clin Oncol (R Coll Radiol) 2001, 13:441-443.